title: TAK-375 Takeda.
abstract: TAK-375 (Ramelteon), a melatonin ML1/MT1 receptor agonist for the potential treatment of primary insomnia, is being developed by Takeda. Takeda submitted an NDA to the FDA for TAK-375 in September 2004.
authors.affiliation: Centre for Chronobiology, Psychiatric University Clinic, Basel, Switzerland. christian.cajochen@pukbasel.ch
authors.forename: Christian
authors.initials: C
authors.lastname: Cajochen
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D007192:Indenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D044122:Receptor, Melatonin, MT1 / Q000819:agonists; D012893:Sleep Wake Disorders / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D007192:Indenes; D044122:Receptor, Melatonin, MT1; C495910:ramelteon